Time Variability of C-Reactive Protein: Implications for Clinical Risk Stratification

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Bogaty, Peter ^a   Dagenais, Gilles R ^a   Joseph, Lawrence ^b   Boyer, Luce ^a   Leblanc, Anne ^a   Bélisle, Patrick ^b   Brophy, James M ^b  

^a LAVAL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE DURATION; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN STABILITY; RECURRENT DISEASE; RISK ASSESSMENT; TIME;

AGED; C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK ASSESSMENT; RISK FACTORS;

EID: 84875993363     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060759     Document Type: Article

References (29)

1. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
2. Libby P, Ridker PM, Maseri A, (2002) Inflammation and atherosclerosis. Circulation 105: 1135-1143.
3. Pepys MB, Hirschfield GM, (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805-1812.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH, (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979.
5. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, et al. (2004) Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351: 2599-2610.
6. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, et al. (1994) The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331: 417-424.
7. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, et al. (2009) Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 38: 217-231.
8. Bogaty P, Boyer L, Simard S, Dauwe F, Dupuis R, et al. (2008) Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease. The RISCA (recurrence and inflammation in the acute coronary syndromes) study. J Am Coll Cardiol 51: 2339-2346.
9. Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, et al. (2012) Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 33: 486-494.
10. Emberson J, Bennett D, Link E, Parish S, Danesh J, et al. (2011) C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet 377: 469-476.
11. Belalcazar LM, Reboussin DM, Haffner SM, Hoogeveen RC, Kriska AM, et al. (2010) A 1-year lifestyle intervention for weight loss in individuals with type 2 diabetes reduces high C-reactive protein levels and identifies metabolic predictors of change: from the Look AHEAD (Action for Health in Diabetes) study. Diabetes Care 33: 2297-2303.
12. Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, et al. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult- 2009 recommendations. Can J Cardiol 25: 567-579.
13. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, et al. (2010) 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 56: e50-103.
14. Clark GH, Fraser CG, (1993) Biological variation of acute phase proteins. Ann Clin Biochem 30: 373-376.
15. de Maat MP, de Bart AC, Hennis BC, Meijer P, Havelaar AC, et al. (1996) Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 16: 1156-1162.
16. Macy EM, Hayes TE, Tracy RP, (1997) Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43: 52-58.
17. Sakkinen PA, Macy EM, Callas PW, Cornell ES, Hayes TE, et al. (1999) Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 149: 261-267.
18. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E, (1999) Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100: 230-235.
19. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, et al. (2001) Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 47: 444-450.
20. Campbell B, Badrick T, Flatman R, Kanowski D, (2002) Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem 39: 85-88.
21. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387-1397.
22. Bogaty P, Brophy JM, Boyer L, Simard S, Joseph L, et al. (2005) Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 165: 221-226.
23. Glynn RJ, MacFadyen JG, Ridker PM, (2009) Tracking of high-sensitivity C-reactive protein after an initially elevated concentration: the JUPITER Study. Clin Chem 55: 305-312.
24. Bogaty P, Poirier P, Simard S, Boyer L, Solymoss S, et al. (2001) Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 103: 3062-3068.
25. Kass R, Raftery A, (1995) Bayes Factors. J Am Stat Assoc 90: 773-795.
26. Woloshin S, Schwartz LM, (2005) Distribution of C-reactive protein values in the United States. N Engl J Med 352: 1611-1613.
27. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. (2010) C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 375: 132-140.
28. Cristell N, Cianflone D, Durante A, Ammirati E, Vanuzzo D, et al. (2011) High-sensitivity C-reactive protein is within normal levels at the very onset of first ST-segment elevation acute myocardial infarction in 41% of cases: a multiethnic case-control study. J Am Coll Cardiol 58: 2654-2661.
29. Bogaty P, J MB, Noel M, Boyer L, Simard S, et al. (2004) Impact of Prolonged Cyclooxygenase-2 Inhibition on Inflammatory Markers and Endothelial Function in Patients With Ischemic Heart Disease and Raised C-Reactive Protein. A Randomized Placebo-Controlled Study. Circulation 110: 934-939.